Search results for "phosphonate"

showing 10 items of 372 documents

Successful treatment of primary chronic osteomyelitis in SAPHO syndrome with bisphosphonates.

2008

Summary The treatment of the painful osteomyelitis in patients with SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) is often a problem. A 53-year-old woman had experienced palmo-plantar pustular skin lesions for four years, and in the past two years complained about progressive breath-and movement-dependent pain of the sternum. On examination she had extensive palmoplantar pustules and a painful swelling in the area of the right sternoclavicular joint. The three-phase bone scintigraphy showed a strong focal enrichment in the right sternoclavicular joint and at the transition from the manubrium to the corpus sterni suggesting active osteo-chondritis. Initially prednisolo…

musculoskeletal diseasesSAPHO syndromemedicine.medical_specialtyHyperostosisDermatologySynovitismedicineHumansAcnemedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteomyelitisAcquired Hyperostosis SyndromeOsteomyelitisMiddle Agedmedicine.diseasePustulosisDermatologySurgeryTreatment OutcomeBone scintigraphyChronic DiseaseFemaleOsteitismedicine.symptombusinessJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

Painful oral aphthous-like lesions in patient with kidney cancer after target therapy and bisphosphonate administration: a case report of adverse dru…

2015

Aim. Tyrosine kinase inhibitors (TKIs) targeting tu- mor angiogenesis and mammalian target of rapamycin inhibitors (mTOR) are indicated for the management of several cancer types, as for renal cell carcinoma (RCC). Oral ulcerations are reported as common adverse drug reactions of mTOR inhibitors and are currently classified as mTOR inhibitor associated stomatitis (mIAS). Interestingly, these lesions appear as aphthous-like stoma- titis rather than the mucositis seen with chemotherapy agent. Case report. A 49 years old male patient underwent to the left radical nephrectomy in May 2014 for clear RCC. From July to October 2014 he was treated with Pazopanib, a tyrosine kinase inhibitor. In Dece…

oral aphthous-like target therapy bisphosphonate adverse drug reactionSettore MED/28 - Malattie Odontostomatologiche
researchProduct

Bisphosphonates and osteonecrosis of the jaw: pathogenetic hypothesis and new preventive measures

2012

BRONJ is a serious oral complication of BP treatment involving the exposure of necrotic maxillary or mandibular bone. We investigated the pathogenetic hypothesis and new preventive measures for BRONJ in patients with bone metastases who received BP zoledronic acid (ZOL) and chemotherapy combined with the antiangiogenic agent bevacizumab (BEV). The pathogenesis of BRONJ is uncertain: the type of BP, duration of the drug use and the occurrence of tooth extractions or other invasive dental procedures during treatment seem to play a major role. A theory that BRONJ is a form of avascular necrosis similar to osteoradio-necrosis also has been proposed. It maybe hypothesized that the combination of…

osteonecrosiSettore MED/06 - Oncologia MedicaBisphosphonate
researchProduct

Epidemiology, clinical manifestations, risk-reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agen…

2014

Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases, of surgica…

osteonecrosibisphosphonatejawSettore MED/28 - Malattie Odontostomatologicheantiresorptive agentcancerdenosumabepidemiologymanagementrisk
researchProduct

Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single …

2022

Background: Medication-Related Osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction mainly associated to bone modifying agents (BMAs). Breast cancer (BC) is the most frequent cancer worldwide. Its therapy can cause cancer treatment-induced bone loss (CTIBL), commonly treated with BMAs. The aims of this retrospective study are: to describe characteristics of BC patients under BMAs for CTIBL; to record any switch to high-dose BMAs; to assess MRONJ onset and to identify any factors associated with it. Patients: Authors included patients referred for MRONJ prevention to the Unit of Oral Medicine (University Hospital of Palermo). Results: Fourteen female BC patients under low-dose BMAs f…

osteonecrosis of the jawbisphosphonatebreast cancerBPosteonecrosis of the jaw; MRONJ; cancer treatment-induced bone loss; CTIBL; breast cancer; osteoporosis; bone metastases; bisphosphonates; BPs; denosumabcancer treatment-induced bone loosteoporosidenosumabPharmacology (medical)MRONJCTIBLbone metastaseOral; Volume 2; Issue 4; Pages: 274-285
researchProduct

Osteonecrosis of the jaws and bisphosphonates : report of fifteen cases: therapeutic recommendations

2007

Recently there have been reports of osteonecrosis of the jaw (ONJ) in patients with chronic therapy with bisphosphonates (Bps). So far three drugs have been linked: Pamidronate of disodium, Zoledronic acid and Alendronate of sodium. It is due to a non detected side effect in clinical trials before commercialization, and reverberates significantly in the quality of life of these patients. Most of the cases are seen in oncology patients that have received long term concurrent antineoplasic therapy and were treated sporadically with steroids, together with Bps endovenous, for treatment of cancer and its symptoms. Among these cases we find the reported by R.E. Marx (1), S.L. Ruggiero (2) and J.…

osteonecrosis of the jawrecommendationsUNESCO::CIENCIAS MÉDICASBisphosphonates:CIENCIAS MÉDICAS [UNESCO]
researchProduct

Bisphosphonates and Oral Pathology II. Osteonecrosis of the jaws : Review of the literature before 2005

2006

Bisphosphonates are bone-turnover modulating drugs which are used in the management of a number of bone diseases ranging from osteoporosis to neoplasic pathology-associated osteolysis. In the last years a number of cases of osteonecrosis of the jaws associated with these drugs have been reported. In this review we analyze the cases published in the literature indexed from 2003 to December 2005. During this period 246 cases were reported, being more frequently associated with women in the sixth decade of life. More frequently associated bisphosphonates were the nitrogenated bisphosphonates (pamidronate, zolendronic acid) and the most common oral antecedent was a dental extraction. Neverthele…

osteonecrosisUNESCO::CIENCIAS MÉDICASreviewBisphosphonates:CIENCIAS MÉDICAS [UNESCO]jaws
researchProduct

THERAPEUTIC OPTIONS IN OSTEOPOROSIS

2010

osteoporosis bisphosphonates calcium vitamin d teriparatide strontium ranelate
researchProduct

Targeting the mevalonate pathway for improved anticancer therapy.

2009

The mevalonate pathway is important for the generation of isoprene moieties thereby providing the basis for the biosynthesis of molecules required for maintaining membrane integrity, steroid production and cell respiration. Additionally, isoprene precursors are indispensable for the prenylation of regulatory proteins such as Ras and Ras-homologous (Rho) GTPases. These low molecular GTP-binding proteins play key roles in numerous signal transduction pathways stimulated upon activation of cell surface receptors by ligand binding. Thus, Ras/Rho proteins eventually regulate cell proliferation, tumor progression and cell death induced by anticancer therapeutics. Lipid modification of Ras/Rho pro…

rho GTP-Binding ProteinsCancer Researchmedicine.medical_treatmentProtein PrenylationMevalonic AcidAntineoplastic AgentsGTPaseModels BiologicalSteroidDrug Delivery SystemsPrenylationCell surface receptorNeoplasmsDrug DiscoverymedicineAnimalsHumansPharmacologyCell DeathDiphosphonatesChemistryCell growthMembrane ProteinsDimethylallyltranstransferaseCell biologyOncologyras ProteinsMevalonate pathwayLipid modificationSignal transductionHydroxymethylglutaryl-CoA Reductase InhibitorsSignal TransductionCurrent cancer drug targets
researchProduct

Dual action of phosphonate herbicides in plants affected by herbivore—Model study on black bean aphid Aphis fabae rearing on broad bean Vicia faba pl…

2008

Abstract The interactions between plants, herbicides and herbivore insects were studied as an aspect of possible side effect of the using of phosphonate herbicides. The experimental system was composed of phosphonate herbicides, broad bean Vicia faba (L.) plants and black bean aphid Aphis fabae (Scopoli). Two means of herbicide application, namely standard spraying and direct introduction of the herbicide into stem via glass capillary, were examined. The results obtained for N-2-piridylaminomethylene bisphosphonic acid and its derivatives show 10 times higher inhibition of the plant growth if glass capillary mode was used. When plants were infested by aphids 24 h after the use of herbicide,…

side effectHealth Toxicology and MutagenesisOrganophosphonatesHost-Parasite Interactionschemistry.chemical_compoundAnimalsAphis fabaeHerbivorebiologyHerbicidesbusiness.industryfungiPublic Health Environmental and Occupational HealthPest controlfood and beveragesGeneral Medicinephosphonate herbicidesbiology.organism_classificationPollutionPhosphonateVicia fabaVicia fabaAphischemistryOlfactometerAgronomyAphidsGlyphosateBlack bean aphidadditive actionbusinessEcotoxicology and Environmental Safety
researchProduct